Biotech Values

[DewDiligence]

Quiz answer: VRTX’s planned phase-2b trial is its first mid-stage HCV trial in some time that does not have a response-guided protocol in at least one arm. From today’s PR (http://finance.yahoo.com/news/Vertex-Announces-12-Week-On-bw-953610313.html?x=0 ):

…pending discussions with regulatory agencies, the company intends to pursue a Phase 2b study evaluating multiple interferon-free combination regimens of INCIVEK, VX-222 and ribavirin with total treatment durations as short as 12 weeks in people with genotype 1 (1a and 1b) hepatitis C who are new to treatment. The new study will not use response-guided treatment criteria.